Prostate cancer is a major cause of male cancer death. In vitro and in vivo data support a role for 1a,25 Dihydroxyvitamin D 3 (1a,25(OH) 2 D 3 ) in regulating the growth and dierentiation of the normal prostate gland yet prostate cancer cells appear signi®cantly less sensitive to this action. Vitamin D 3 receptor (VDR) content or mutational status do not correlate clearly with the antiproliferative eects of 1a,25(OH) 2 D 3 and therefore it is unclear why prostate cancer cell lines are signi®cantly less sensitive to this action. We hypothesized that the antiproliferative responses of prostate cancer cells to 1a,25(OH) 2 D 3 are suppressed by a process involving histone deacetylation. Sodium butyrate (NaB) and trichostatin A (TSA) are inhibitors of histone deacetylase (HDAC) activity. Low doses of NaB or TSA (300 mM and 15 nM respectively), which alone were relatively inactive, synergized with 1a,25(OH) 2 D 3 in liquid and semi-solid agar to inhibit the growth of LNCaP, PC-3 and DU-145 prostate cancer cells. Still greater synergy was observed between vitamin D 3 hexa¯uoride analogs and either NaB or TSA. The mechanism appeared to involve neither the cyclindependent kinase inhibitor, p21
Introduction
Prostate cancer is one of the most common cancers in European and American males and has a high mortality rate (Landis et al., 1998; Rosenthal, 1998) . For invasive disease, surgery and radiation therapy options are not applicable and instead current therapy is focused principally around androgen ablation. This induces a remission, but in the majority of cases, the tumour subsequently re-emerges in an androgenindependent form for which there is no curative options currently available. Much research has focused on agents such as retinoic acids and the seco-steroid hormone 1a,25-Dihydroxyvitamin D 3 (1a,25(OH) 2 D 3 ) to induce either apoptosis or dierentiation as an alternative therapy for androgen-independent prostate cancer (Liang et al., 1999; de Vos et al., 1997; Skowronski et al., 1994; Hedlund et al., 1997) .
Multiple lines of evidence have emerged which indicate that 1a,25(OH) 2 D 3 plays a role in controlling the growth and dierentiation of normal prostate cells. In vivo, 1a,25(OH) 2 D 3 co-operates with testosterone to induce dierentiation of prostate epithelial cells (Konety et al., 1996) . Normal and malignant prostate cells synthesize 1a,25(OH) 2 D 3 from 25-hydroxyvitamin D 3 , possibly suggesting an autocrine route for 1a,25(OH) 2 D 3 signalling in this tissue (Schwartz et al., 1998) . Similarly, epidemiological evidence supports a role of 1a,25(OH) 2 D 3 signalling in regulating prostate cell growth (Schwartz and Hulka, 1990; Hanchette and Schwartz, 1992) .
Other data indicates that dysregulation of this hormone signalling contributes to the development of prostate cancer. Polymorphisms within the VDR are strongly associated with the incidence of prostate cancer, possibly as a result of altered transcriptional activity (Habuchi et al., 2000; Ingles et al., 1997; Watanabe et al., 1999; Jurutka et al., 2000) . Similarly growth of cancer cells, despite expressing comparable levels of wild-type receptor, is signi®cantly less inhibited by 1a,25(OH) 2 D 3 than normal prostate epithelial. For example, of the established prostate cancer cell lines only LNCaP and ALVA-31 are signi®cantly growth inhibited by 1a,25(OH) 2 D 3 . By contrast, PPC-1, DU-145, PC-3 and TSU-Pr1 cell lines are essentially insensitive to this antiproliferative action requiring concentrations of greater than 1 mM to inhibit cell or colony growth by more than 50% (Skowronski et al., 1994; Hedlund et al., 1996; Miller et al., 1995; Campbell et al., 1997; Krill et al., 1999; Peehl et al., 1993) despite expression of wild-type VDR . Burnstein and co-workers used classical binding analysis of VDR in combination with transient transactivation studies to examine the molecular basis of 1a,25(OH) 2 D 3 activity in prostate cancer cells and concluded that VDR content and transcriptional activity alone do not dictate cellular responsiveness to 1a,25(OH) 2 D 3 signalling (Zhang et al., 1997) . Resolution of the mechanisms by which prostate cancer cells are able to resist the anti-proliferative action of 1a,25(OH) 2 D 3 is essential if it is to be used successfully in dierentiation therapy for prostate cancer.
There is signi®cant variation in the arrangement and sequence of the vitamin D 3 response elements (VDRE) in the enhancer regions on the promoters of dierent 1a,25(OH) 2 D 3 target genes such as the cyclin-dependent kinase inhibitor, p21
(waf1/cip1) and 25(OH)D 3 -24-hydroxylase (CYP24) (Chen and DeLuca, 1995; Liu et al., 1996) . We hypothesized that variations in the nucleotide sequence allow selective targeting by dierent VDR-containing enhansome complexes. Initiation of transcription requires chromatin remodelling to facilitate signalling to the RNA polymerase II holoenzyme. Steroid hormone receptor co-activator and co-repressor proteins regulate this process by altering the level of histone acetylation (HAT) and histone deacetylation (HDAC); a relaxed, acetylated chromatin structure is essential to promote liganddependent access to the pre-initiation complex (Xu et al., 1999) . Thus the altered activity and/or expression of such VDR-cofactors may in turn in¯uence HDAC activity on key VDRE and thereby account for dierences in gene expression between normal and malignant prostate (Torchia et al., 1997; Rachez et al., 1999; Gurnstein, 1997) . We therefore examined whether prostate cancer cells that displayed poor anti-proliferative responses to 1a,25(OH) 2 D 3 could be made sensitive by co-treatment with the HDAC inhibitors sodium butyrate and trichostatin A.
Results

Transactivation of luciferase reporter construct
We utilized a series of luciferase reporter constructs to examine the response of the p21-Luc luciferase reporter construct to 1a,25(OH) 2 D 3 (100 nM) and compared its regulation to the ATRA-driven bRARE-Luc ( Figure  1 ). In our preliminary investigations to optimize transfection conditions we examined the dierences between utilising a number of dierent strategies to normalize signal and found that there were no signi®cant dierences between using either the signal of a co-transfected constitutively active reporter (e.g. Renilla Luciferase) or total protein and thus all subsequent studies were normalized to total protein.
In all three prostate cancer cell lines we found only relatively weak ligand-dependent transactivation of the p21-Luc construct, which was not signi®cantly altered by the co-transfection of VDR (data not shown). For example, in PC-3 cells, treatment of p21-Luc with 1a,25(OH) 2 D 3 increased the mean RLU/g protein from 459 ± 524 (1.14-fold increase). By comparison the ATRA-driven bRARE-Luc was transactivated to a signi®cantly greater degree from 394 ± 2762 RLU/g protein, a sevenfold increase in ligand-dependent transactivation (P50.0001). Similar patterns were observed with all three-cell lines. Although we are cautious not to over-interpret these data we suggest they re¯ect the relative suppression of 1a,25(OH) 2 D 3 antiproliferative signalling in the prostate cancer cells. This is also supported by the observation that the p21-Luc luciferase reporter construct was more readily transactivated (2.8-fold) in MCF-7 breast cancer cells (data not shown). We and others have shown that these cells are signi®cantly more sensitive to the antiproliferative action of 1a,25(OH) 2 D 3 than LNCaP, PC-3 or DU-145 and readily induce p21 (waf1/cip1) protein expression in response to 1a,25(OH) 2 D 3 signalling with a concomitant G1 cell cycle arrest (Verlinden et al., 1998) . Luciferase reporter assays were used to measure gene transactivation. LNCaP, PC-3 and DU-145 cells were set up in 6-well plates at a density of 1610 5 cells/well. Cells were transfected with either CYP24-Luc, p21-LUC or b-RARELuc using Lipofectamine reagent. Transfected cells containing either CYP24-Luc or p21-LUC were dosed with 1a25-(OH) 2 D 3 (100 nM), cells containing b-RARE-Luc were dosed with ATRA (100 nM). Luciferase activity was analysed and normalized to total protein. Each data point represents the mean of three separate experiments undertaken in duplicate wells. **P50.001, ***P50.0001
Oncogene HDAC inhibitors and 1a,25 Dihydroxyvitamin D 3 in prostate cancer SF Rashid et al It is interesting to note that ATRA-mediated antiproliferative action is also compromised in the androgen-independent cell lines (PC-3 and DU-145) as a result of loss of ATRA-induced expression of RARb, probably due to promoter methylation (Campbell et al., 1998) .
1a,25(OH) 2 D 3 synergizes with HDAC inhibitors to inhibit cell growth Individual 1a,25(OH) 2 D 3 , TSA and NaB dose-response assays were performed in each of the prostate cancer cell lines to establish those doses that inhibited cell growth by 25% or less. These doses, were determined to be 100 nM 1a,25(OH) 2 D 3 , 15 nM TSA and 300 mM for NaB (data not shown), and were used subsequently for combinatorial studies. Initially the eects on cell proliferation were determined both by counting cells in culture after 96 h ( In all three cell lines, the combination of 1a,25(OH) 2 D 3 with either TSA or NaB resulted in synergistic inhibition of cell growth. For example, 1a,25(OH) 2 D 3 alone inhibited growth of LNCaP cells by 18+2.1% (mean percentage growth+s.e.m.), as assessed by cell counts at 96 h, compared to 27+3.2% by NaB and 62.2+3.2% (P50.05) in the presence of both agents. Similarly in this cell line, the more speci®c HDAC inhibitor TSA, synergized with 1a,25(OH) 2 D 3 to inhibit growth by 52.9+5.8% (P50.05). These eects were observed also in PC-3 and DU-145 cells.
We also validated a 96-well plate luminescence-based assay to measure cellular ATP as a rapid, accurate, reproducible and sensitive measure of cell growth thus applicable to screening multiple treatment combinations. Only small (non-signi®cant)¯uctuations in the action of individual agents were detected between the two assays. In general, similar synergisms were observed with LNCaP and PC-3 using either the cell counting assay or the 48 h ATP bioluminescent assay, whereas DU-145 appeared more resistant to the action of the agents in this latter assay (Figure 2 and summarized in Table 1 ).
Transactivation of target genes by the combination of 1a,25(OH) 2 D 3 with either HDAC inhibitor Other workers investigating the interaction of histone acetylation and steroid hormone receptor activity have demonstrated that HDAC inhibitors either alone or in combination with ATRA can transactivate even transiently transfected reporter constructs potentially by regulating the acetylation status of non-histone proteins (Lin et al., 1998; Lea and Randolph, 1998) . We therefore investigated whether the synergistic interaction of 1a,25(OH) 2 D 3 in combination with either of the HDAC inhibitors could be observed using transactivation of VDRE-containing reporter constructs for two well established 1a,25(OH) 2 D 3 target genes, namely CYP24 and p21 (waf1/cip1) . Synergistic transactivation was observed in certain cell line/ reporter construct combinations by 1a,25(OH) 2 D 3 with NaB. For example, DU-145 cells transfected with CYP24-Luc and treated with 1a,25(OH) 2 D 3 (100 nM) alone resulted in 1.3-fold increase, NaB (300 mM) alone resulted in 5.3-fold increase whereas the combination synergized, resulting in a 9.8-fold activation (P50.001) (Figure 3a) . A similar enhancement of 1a,25(OH) 2 D 3 -mediated transactivation by NaB was observed with LNCaP and PC-3 cells transfected with p21-Luc (data not shown). However, similar experiments undertaken in all three cell lines with TSA and either reporter construct revealed that this agent, in the current transient reporter system, had no transactivation ability when used alone, nor did it additively or synergistically enhance the transactivation ability of 1a,25(OH) 2 D 3 (Figure 3a and data not shown).
We examined the eect of these treatments on transactivation of genomic targets by measuring CYP24 and p21 (Figure 3b ). Furthermore the HDAC inhibitors also resulted in approximately twofold increase in CYP24 mRNA. The co-treatment of 1a,25(OH) 2 D 3 with NaB resulted in additive fold increase in mRNA (3.8-fold) although this did not occur with TSA. By contrast, the induction of p21 (waf1/cip1) mRNA was only increased by treatment with NaB (1.5-fold); cotreatments did not enhance this eect.
Synergistic growth inhibition is not cell cycle arrest mediated but involves apoptosis
Cell cycle and apoptosis analyses were undertaken in all three cell lines in an eort to investigate the mechanism of the synergistic growth inhibition. As has been reported previously by ourselves and others, modest 1a,25(OH) 2 D 3 -mediated increases in G1 of the cell cycle were detected in LNCaP and PC-3 cells, when treated with 1a,25(OH) 2 D 3 . However further cell cycle analysis at 24, 48, 72 and 96 h after co-treatment with 1a,25(OH) 2 D 3 and either NaB or TSA resulted in only modest sub-additive changes in cell cycle pro®les, possibly re¯ecting the weak induction of p21 (waf1/cip1) detected above. By contrast,¯asks treated in parallel revealed a dramatic induction of apoptosis as revealed by increase of DNA strand breaks and loss of mitochondrial membrane integrity. For example, although NaB initiated some limited apoptosis (16.2+2.3% with LNCaP cells), as has been described previously (Ellerhorst et al., 1999; Bernhard et al., 1999) , the combination of either 1a,25(OH) 2 D 3 with either HDAC inhibitor resulted in additive (NaB) and synergistic (TSA; P50.05) induction of apoptosis in all three cell lines. For example, the predicted, additive induction of apoptosis in PC-3 cells was (14.0+0.9%). By contrast, the observed value was signi®cantly greater (27.8+2.7%; P50.05); (Figure 4b ,c). Similar data was also obtained with DU-145 cells (data not shown). These data were re¯ected by those generated by investigating mitochondrial membrane integrity. Representative staining for PC-3 cells is shown in Figure 4c . An initial hallmark of apoptosis is the loss of mitochondrial membrane integrity and therefore a loss of membrane potential. The mitosensor dye aggregates in the mitochondria of healthy cells and uoresces red, in apoptotic cells the dye subsequently remains in the cytoplasm as monomers and¯uoresces green. These images represent a dierent, earlier, stage of apoptosis, and therefore it is dicult to make direct, quantitative comparisons to the TUNEL assay data. However they do re¯ect the trend towards much greater apoptosis by co-treatment of agents. Microscope analysis of the PC-3 cell line after combination treatment revealed the presence of dramatically more apoptotic cells occurring where combination treatments were used.
Hexafluoride analogs of 1a,25(OH) 2 D 3 enhance the antiproliferative potency
Transcriptional silencing of a subset of antiproliferative genes but maintenance of others, such as CYP24 may aord a number of bene®ts to prostate cancer cells. This recently identi®ed putative oncogene may, at a minimum, promote cellular insensitivity to 1a,25(OH) 2 D 3 by inducing more rapid catabolism of the hormone (Albertson et al., 2000; Ly et al., 1999) . Furthermore it may provide other advantages, as we have recently demonstrated that CYP24-mediated metabolism of 1a,25(OH) 2 D 3 gives rise to metabolites that promote other cellular eects including increased survival and proliferation (Campbell et al., 1999a; Rashid et al., 2001) . In an eort to overcome the associated diculties of CYP24 metabolism we have utilized a series of vitamin D 3 analogs that have hexa¯uoride motifs on the side-chain thereby protecting the molecule from CYP24 metabolism . The ability of the hexa¯uoride analogs (LH and LT) to enhance the combinatorial antiproliferative eects seen with the parent molecule and HDAC inhibitors were investigated in both a time and dosedependent manner using the ATP bioluminescent assay at 48 and 96 h and clonogenic assay at 14 days.
With all three cell lines we found an analog-mediated enhancement of eect that increased with time. For example, when LNCaP cells were exposed to TSA in combination with a reduced dose (10 nM Figure 5a and Table 2 ).
Extension of the assay duration to 14 days, in a clonogenic assay, resulted in signi®cantly greater additive growth inhibition for the combination of 1a,25(OH) 2 D 3 with TSA (64.9+3.2%, P50.001).
Similarly there was also an approximate doubling of the eect of either analog (LH or LT) with TSA in the clonogenic assay, for example LH synergized with TSA to inhibit colony formation (83.7+7.7%; P50.001)). The values of inhibition with either LH/TSA (83.7+7.7%) or LT/TSA (94.4+1.6%) were both signi®cantly greater than 1a,25(OH) 2 D 3 /TSA (P50.05 and P50.005 respectively; Figure 5b and Table 2 ). A similar, time-dependent, progression of eectiveness, notably with the analogs, was seen with PC-3 cells (Table 2 ) and DU-145 cells (data not shown).
The above studies highlighted the striking therapeutic potential for potent vitamin D 3 analogs, such as LH, to be used at low, clinically achievable, doses in combination with HDAC inhibitors. In an eort to investigate this more thoroughly we undertook a series of dose-response studies in the androgen-independent cell lines PC-3 and DU-145 with either 1a,25(OH) 2 D 3 or the analog LH at a ®xed time point (48 h) using the ATP bioluminescent assay. This assay and time point combination is able to dierentiate between the sensitivities of the cells. For example in the initial studies ( Figure 2 ) the combination of 1a,25(OH) 2 D 3 / TSA was only sub-additive in DU-145 cells although synergistic with PC-3 cells. Figure 6 shows the relationships between combinations involving either The eects were measured by cell counting and ATP bioluminescent assay as described in the Materials and methods and were de®ned as follows: Synergistic eects (Syn) were those with an experimental value signi®cantly greater than the predicted value, additive eects (Add) were those where the experimental value did not signi®cantly dier from the predicted value, sub-additive eects (Sub) were those where the experimental value was signi®cantly less than the predicted value 1a,25(OH) 2 D 3 /NaB and LH/NaB (Figure 6a,c) , or 1a,25(OH) 2 D 3 /TSA and LH/TSA (Figure 6b,d ). Many combinations involving LH and either HDAC inhibitor were signi®cantly more potent. Most dramatically analog-dependent enhancement of eect was seen across a broad range of doses (0.1 ± 100 nM) with LH and TSA in both PC-3 and DU-145 where there was signi®cantly increased antiproliferative potency at lower doses. With doses as low as 1 nM (a readily clinically achievable dose) 1a,25(OH) 2 D 3 in combination with TSA resulted in sub-additive inhibition of cell growth (25.2+3.7%) of cell growth. However the same dose of LH combined with TSA was signi®cantly more potent (51.9+3.6%; P50.02). Similar patterns were observed with DU-145 cells (Figure 6c,d ).
Discussion
The central theme of the current study is that a lesion exists in the normal signalling of 1a,25(OH) 2 D 3 in prostate cancer cells, such that the growth regulatory signalling of this hormone is suppressed. The response of the prostate cancer cell lines, used in the current study, is very well established (Skowronski et al., 1994; Hedlund et al., 1996; Miller et al., 1995; Krill et al., 1999; Peehl et al., 1993) . We hypothesized that the reduced ability of these cells to be growth inhibited by 1a,25(OH) 2 D 3 was a result of an inability to transactivate critical 1a,25(OH) 2 D 3 -target genes responsible for its antiproliferative/prodierentiative behaviour, via a mechanism involving histone deacetylation. Therefore, we investigated whether 1a,25(OH) 2 D 3 -mediated antiproliferative signalling could be restored by co-treatment with HDAC inhibitors. Dramatically, HDAC inhibitors in combination with 1a,25(OH) 2 D 3 synergized together to inhibit growth through a pathway that involved principally induction of apoptosis. This eect was observed in three dierent cell lines, by four dierent assay methods, using three dierent vitamin D 3 compounds in combination with either of two dierent HDAC inhibitors.
We hypothesized initially that an inability to modulate p21 (waf1/cip1) mRNA may be the central defect in signalling of 1a,25(OH) 2 D 3 in prostate cancer cells. Examination of induction of mRNA by Northern blots and quantitative RT ± PCR data demonstrated a signi®cant discrepancy between the regulation of CYP24 and p21
, most noticeably in the more aggressive cells such as PC-3 and DU-145, as inferred by previous studies (SFR unpublished observations and Miller et al., 1995; Campbell et al., 1997; Zhang et al., 1997; Zhuang and Burnstein, 1998) . Thus insensitivity to 1a,25(OH) 2 D 3 does not arise because of a global inability to modulate 1a,25(OH) 2 D 3 target genes. In the current study the sensitivity to 1a,25(OH) 2 D 3 of all cells examined was increased dramatically by co-treatment with the HDAC inhibitor TSA. However, in neither the luciferase nor the RT ± PCR assays did we observe any enhanced p21
transactivation by the combination of TSA with 1a,25(OH) 2 D 3 . Critically, the principal mechanism of growth inhibition appeared to be induction of apoptosis rather than cell cycle arrest, supporting further a diminished role for p21
(waf1/cip1) in mediating the antiproliferative eects. Thus, although we cannot exclude a contribution from transcriptional upregulation of p21 (waf1/cip1) by 1a,25(OH) 2 D 3 and NaB, via speci®c NaB-response elements (Pace et al., 2000; Iowa et al., 1999) , we believe the contribution at the dose used in the current study, is minimal.
Escape from the normal control of apoptosis is integral to the transformation process in prostate (waf1/cip1) by mRNA. DU-145 cells (2610 6 cells/¯ask) were allowed to adhere overnight and then treated with 100 nM 1a25-(OH) 2 D 3 , 300 mM NaB and 15 nM TSA or in combination (either 1a25-(OH) 2 D 3 plus NaB or 1a25-(OH) 2 D 3 plus TSA). Total RNA was isolated; reverse transcribed and the target genes ampli®ed according to the Materials and methods. Each data point represents the mean of three separate experiments undertaken in triplicate wells. *P50.05 cancer and PC-3 and DU-145 cells display many alterations that are associated with metastatic androgen-independent cancer, including aberrant p53 function and dysregulation of normal apoptotic responses (Carrol et al., 1993; Ewing et al., 1995; Isaacs et al., 1994; Tamimi et al., 1996; Mackey et al., 1998 ) and furthermore do not readily undergo apotosis when exposed to 1a,25(OH) 2 D 3 Zhuang and Burnstein, 1998) . Interestingly, Carlberg and co-workers have demonstrated that either dierent VDR co-repressors complexes or structurally dierent vitamin D 3 analogs demonstrate VDRE selectivity (Quack and Carlberg, 1999; Nayeri and Carlberg, 1997; Danielsson et al., 1997; Polly et al., 2000) . These ®ndings would allow for dierential regulation of genes by 1a,25(OH) 2 D 3 , within the same cell line, and disruption of a speci®c co-factor, such as a co-repressor with associated HDAC activity, would consequently silence a speci®c subset of 1a,25(OH) 2 D 3 -responsive genes. We postulated therefore that a normal aspect of 1a,25(OH) 2 D 3 antiproliferative signalling in prostate epithelial cells is to regulate apoptosis and that in cancer cells dysregulated co-repressor activity suppresses this. In the current study a pronounced synergistic induction of apoptosis was seen in all three cell lines by the co-treatment of 1a,25(OH) 2 D 3 with TSA.
The dysregulation of steroid hormone receptor coactivator and co-repressor proteins has been described in a number of cancers. For example, in acute promyelocytic leukaemia, chromosomal translocations (PML ± RAR and PLZF ± RAR) generate chimeric proteins that contain part of the retinoic acid receptor-a (RARa). These chimeras inappropriately recruit the co-repressors SMRT and NCoR, thereby suppressing normal signalling by ATRA (Lin et al., 1998; Grignani et al., 1998) 5 cells/¯ask, and treated with either single (100 nM 1a25-(OH) 2 D 3 , 300 mM NaB or 15 nM TSA) or combinations (1a25-(OH) 2 D 3 plus NaB or TSA) of agents. Cells were re-dosed (with addition of fresh media) after 48 h and harvested after 96 h. All cells were harvested (both in the medium and those remaining adherent), and ®xed in methanol free formaldehyde. DNA breaks were labelled with BrdUTP by TdT and tagged with FITC-anti BrdUrd anbtibody. Cells were stained with PI and analysed using a¯ow cytometer. Each data point represents the mean of three separate experiments undertaken in triplicate wells. *P50.05. (c) Mitochondrial membrane integrity was measured in PC-3 cells. Cells were plated in the same manner as for end-labelling assay. Total cells (both those remaining adherent and those¯oating) were harvested and stained with Mitosensor dye. Cells undergoing apoptosis lose mitochondrial membrane integrity and the mitochondria do not¯uoresce red, instead general green staining is observed in the cytoplasm Numerous studies have investigated NaB and TSA and found them to be potent inducers of cell cycle arrest, dierentiation and apoptosis in a variety of normal and cancer cell types all be it at signi®cantly higher doses than used in the current study (Lin et al., 1998; Grignani et al., 1998; Lea and Randolph, 1998; Bernhard et al., 1999; Medina et al., 1997; Yoshida et al., 1990) . Furthermore a number of previous studies have investigated the action of NaB in combination with 1a,25(OH) 2 D 3 (and its analogs) and reported a synergistic eect on cell growth and dierentiation (Yoshida et al., 1990 (Yoshida et al., , 1992 Yoneda et al., 1984; Tanaka et al., 1989; Maiyar and Norman, 1992) .
However this is the ®rst study, to the best of our knowledge, to consider the combination of 1a,25(OH) 2 D 3 with the much more speci®c HDAC inhibitor TSA, at low doses (less than 100 nM). The use of a speci®c HDAC inhibitor suggests strongly that the augmentation of 1a,25(OH) 2 D 3 eects with NaB is principally a consequence of HDAC inhibition rather than the intrinsic transcriptional activity of NaB.
Analogs of 1a,25(OH) 2 D 3 have been developed in an attempt to enhance the antiproliferative potency and promote their application in cancer dierentiation therapy. We, and others, have previously identi®ed hexa¯uoride analogs, such as 1a,25-(OH)2-16-ene-23-yne-26,27-hexa¯uoride-19-nor-D 3 (LH), as being highly potent in a diverse range of cancer cell types, largely as a result of its ability to resist CYP24-mediated metabolism Koike et al., 1997; Evans et al., 1999; Munker et al., 1996; Anzano et al., 1994) . Furthermore we have investigated ways to enhance the antiproliferative potency of these, and other, analogs for example, by combination with retionids (Campbell et al., 1998 (Campbell et al., , 1999b . However few if any of these strategies demonstrated potent action against all cell lines especially the highly recalcitrant, androgenindependent DU-145. The current study has identi®ed the combination of TSA, a selective HDAC inhibitor, with analog LH as a particularly potent apoptosisinducing treatment with sustained activity against all three prostate cancer cell lines. This combination was at least 500 times more potent than 1a,25(OH) 2 D 3 /TSA in PC-3 cells, and more so with DU-145 cells.
These ®ndings ®t with a model whereby a key, as yet unknown, pro-apoptotic 1a,25(OH) 2 D 3 -target gene is transcriptionally silenced by a promoter speci®c corepressor with HDAC activity. Furthermore HDAC inhibitors, such as NaB or suberanilohydroamic acid (Cohen et al., 1999) , may be used in vivo to augment dramatically the antiproliferative eects of potent, noncalcemic, vitamin D 3 analogs against androgen-independent prostate cancer in a p53-independent manner. These compounds are pharmacologically available agents which would be utilized at clinically available doses and therefore represent a highly attractive clinical option.
Materials and methods
1a,25(OH) 2 D 3 , All trans retinoic acid and HDAC inhibitors
The vitamin D 3 compounds, 1a,25(OH) 2 D 3 , 1a,25-(OH)2-16,23E-diene-26,27-hexa¯uoride-D 3 (LT), 1a,25-(OH)2-16-ene-23-yne-26,27-hexa¯uoride-19-nor-D 3 (LH), all trans retinoic acid (ATRA) and trichostatin A (TSA) (Sigma, Poole, UK) were all stored as 1 mM stock solutions in ethanol at 7208C. Sodium butyrate (NaB) (Sigma) was used as a freshly made 200 mM stock solution in PBS.
Cell culture
The prostate cancer cell lines LNCaP, PC-3 and DU-145 were obtained from the American Type Culture Collection 3 cells/well and treated with either vitamin D 3 compound alone (10 nM), 300 mM NaB or 15 nM TSA) or in combination (either vitamin D 3 compound plus NaB or vitamin D 3 compound plus TSA). The cells were incubated for 96 h and then total ATP was measured in each well using a luciferase-dependent method according to the Materials and methods and compared to untreated control. (b) LNCaP cells were grown in a two-layer, soft-agar assay system in the presence of the same treatments as used in (a and b). After 14 days growth colony number was enumerated and compared to untreated control. Each data point represents the mean of three separate experiments undertaken in triplicate wells. *P50.05 (ATCC, Rockville, MD, USA). MCF-7 breast cancer cells were obtained from Dr Kay Colston (St. George's Hospital, London). All cells were maintained in RPMI 1640 medium (ATCC), supplemented with 100 units/ml penicillin, 100 mg/ ml streptomycin and 10% foetal bovine serum (Gibco ± BRL, Paisley) at 378C in a humidi®ed atmosphere of 5% CO 2 in air. Cells were passaged by trypsinising with trypsin-EDTA (Gibco ± BRL).
Luciferase reporter plasmids
A luciferase reporter construct containing the 5 half-site VDRE from the promoter/enhancer region of rat CYP24 (Kerry et al., 1996) , (CYP24-Luc) was generated by cloning the sequence 5'-GATCAGAGCGCA CCCGCTGAACCC-TGCTGCCGGCGCCCTCACTCACCTCGCTGACTCCAT-G-3' (VDRE half sites in bold), synthesized as complementary oligonucleotides (Alta bioscience, Birmingham University, Birmingham, UK with BamHI compatible ends). Oligonucleotides were phosphorylated with ATP and T4 polynucleotide kinase (Pharmacia Biotech, St Albans, UK), complementary strands were annealed and cloned into a luciferase reporter vector containing a minimal TK promoter to give the ®nal pBLTKpA3LUC (CYP24-Luc). The reporter gene construct was sequenced to con®rm the presence of a single copy of the correctly orientated VDRE oligo. A similar reporter construct containing the VDRE from the promoter/ enhancer region of p21 (waf1/cip1) (p21-Luc) was a generous gift of Dr Leonard P Freedman (Cell Biology & Genetics, SloanKettering Institute, NY, USA). Similarly a reporter construct containing the retinoic acid response element (RARE) from the promoter/enhancer region of the retinoic acid receptor b (bRARE-Luc) was a generous gift of Dr Elizabeth Allegretto (Department of Medicinal Chemistry, Ligand Pharmaceuticals, Inc., San Diego, CA, USA).
Transactivation of reporter constructs
Transfection conditions for each cell line were optimized, using pCMV-luciferase as a positive control, with LipofectAmine (Gibco ± BRL) according to the manufacturer's instructions. Each cell line was then transfected separately with CYP24-Luc, p21-Luc and bRARE-Luc. Following transfection, the cells were kept in RPMI media containg 10% charcoal-stripped foetal calf serum and dosed with either 100 nM 1a,25(OH) 2 D 3 , 300 mM NaB or 15 nM TSA, alone or in combination (CYP24-Luc, p21-Luc) or 100 nM ATRA (bRARE-Luc). After a subsequent 24 h, each well was harvested by rinsing twice with PBS, lysing with 500 ml Reporter Lysis Buer, (Promega, Southampton, UK) and scraping. The lysates were spun at 12 000 g for 2 min at 48C, frozen at 7708C and rapidly thawed. Luciferase activity was measured by adding 100 ml Luciferase Assay Reagent (Promega) at room temperature to 40 ml of each sample using a micro plate luminometer (Berthold Detection Systems, Fisher Scienti®c Ltd.).
Growth of prostate cancer cell lines in the presence of vitamin D 3 compounds and HDAC inhibitors
The action of individual agents alone and in combination was examined by a number of dierent proliferation assays. Initially the eects of 1a,25(OH) 2 D 3 , TSA and NaB alone were titrated using a 72 h liquid culture growth assay in which agent, at varying concentrations, was added to 24-well plates (1610 4 cells/well). A dose of either 1a,25(OH) 2 D 3 , TSA or NaB, which alone inhibited cell growth approximately 25% was interpolated from single agent growth curves for use in the various combination assays. The combined agents (i.e. either 1a,25(OH) 2 D 3 (100 nM) plus TSA or 1a,25(OH) 2 D 3 plus NaB) were added to wells containing 5610 3 cells and cultured for 96 h with a re-dose after 48 h with fresh media containing appropriate agent. In both the 72 and 96 h assays total cells remaining adherent were harvested, washed and re-suspended in PBS and stained with trypan blue (Sigma) before being counted using a haemocytometer.
To investigate the increased eectiveness of the hexauoride analogs of 1a,25(OH) 2 D 3 in combination with the HDAC inhibitors we undertook 96-well plate dose-response studies that measured cellular ATP. The cell proliferation assay (ViaLight HS, LumiTech, Nottingham, UK) was used with previously optimized conditions according to the manufacturers instructions. Brie¯y, cells at the same density as used in the 24-well assay were plated into 96-well white walled tissue culture treated plates (2610 3 cells/well) (Fisher Scienti®c Ltd. Loughborough, UK). The cells were exposed to various treatments; varying concentrations of 1a,25(OH) 2 D 3 LH, LT, in combination with either TSA (15 nM) or NaB (300 mM). The ®nal volume of the well was The eects were measured by ATP bioluminescent assay or colony formation in soft agar as described in the Materials and methods and were de®ned as follows: Synergistic eects (Syn) were those with an experimental value signi®cantly greater than the predicted value; additive eects (Add) were those where the experimental value did not signi®cantly dier from the predicted value; sub-additive eects (Sub) were those where the experimental value was signi®cantly less than the predicted value. ND=not determined. *P50.05, **P50.001 made up to 100 ml with media and incubated for either 48 or 96 h having been re-dosed after 48 h. After the incubation period 100 ml of nucleotide releasing reagent was added and the cells were left for 30 min at room temperature to extract the ATP. Liberated ATP was quantitated by addition of 20 ml of ATP monitoring reagent (containing luciferin and luciferase) by using a micro plate luminometer (Berthold Detection Systems, Fisher Scienti®c Ltd.). The eect of speci®c treatment/cell line combinations was examined also by clonal proliferation in soft agar. Trypsinized and washed single-cell suspensions of cells from 80% con¯uent cultures were counted and plated into 24-well¯at bottom plates using a two-layer soft-agar system with a total of 1610 3 cells per well in a total volume of 400 ml per well as described previously . Both layers were prepared with sterile agar (1%) that had been equilibrated previously at 428C. The vitamin D 3 compounds (10 nM), or HDAC inhibitors NaB (300 mM) and TSA (15 nM) were added to the wells prior to the addition of the under layer. The cells were mixed into the top layer and plated onto the pre-set feeder layer. After 14 days incubation in a humidi®ed atmosphere of 5% CO 2 at 378C, the colonies (550 cells) were counted under an inverted microscope.
All experiments were performed three times and in triplicate.
Quantitative RT ± PCR
Total RNA from each cell line was extracted with TRIZOL reagent (GIBCO ± BRL, Grand Island, NY, USA) and treated for 30 min at 378C with RQ1 RNAse-free DNAse (Promega) in 100 mM Tris-HCl, pH 9.0, 500 mM KCl and 2 mM MgCl 2 . The cDNA was prepared from DNAse-treated, phenol-chloroform-extracted mRNA (1 mg) by reverse transcription with M-MLV (Promega) at 428C for 60 min in the presence of 100 mM Tris-HCl, pH 9.0, 500 mM KCl and 2 mM MgCl 2 , 100 pM random hexamers (Pharmacia, Pisacataway, NJ, USA), 2 mM dNTP and 20 U RNAsin (Promega) in a 20 ml reaction volume. Expression of p21 (waf1/cip1) , and CYP24 cDNA were detected by PCR ampli®cation with the primers pairs as follows; p21 (waf1/cip1) was a 201 bp fragment generated with sense primer 5'-gagcgatggaacttcgactt-3', anti- 3 cells/well and treated with vitamin D 3 compound (0.1 to 100 nM) and HADC inhibitors alone (data not shown) or in combination with 300 mM NaB (a) or 15 nM TSA (b). Total ATP was measured in each well using a luciferase-dependent method according to the Materials and methods and compared to untreated control. Each data point represents the mean of three separate experiments undertaken in triplicate wells. (c and d) DU-145 and PC-3 cells were plated into 96-well plates at a density of 2610 3 cells/well and treated. Synergistic eects (Syn) were those with an experimental value signi®cantly greater than the predicted combined value, additive eects (Add) were those where the experimental value did not signi®cantly dier from the predicted combined value, sub-additive eects (Sub) were those where the experimental value was signi®cantly less than the predicated combined value. Each data point represents the mean of three separate experiments undertaken in triplicate wells sense primer 5'-caggtccacatggtcttcct-3', CYP24 was a 402 bp fragment generated with sense primer 5'-ctaccgcaaagaaggctacg-3', antisence primer 5'-agagtgtgtccctgccagac-3'. Semiquantitative PCR was performed using 18 s cDNA as an internal control. Multiplex ampli®cation of 18S rRNA and product was undertaken using 18S primers and competimers according to the manufacturer's instructions (Ambion, Witney, UK). Brie¯y, the linear ampli®cation range for 18S primer and competimer (ratio 2 : 8) and product primers was optimized in the multiplex conditions and determined to be 31 cycles.
For each reaction, 2 ml of template was ampli®ed in the presence of 100 mM Tris-HCl, pH 9.0, 500 mM KCl, 5 mM MgCl 2 , 0.2 mM dNTP, 300 mM. M primer, and 1.5 U TAQ polymerase (Promega) in a ®nal volume of 30 ml. The mixture was overlaid with mineral oil and ampli®ed in a thermal cycler with PCR cycle conditions as follows: 948C for 1 min, 608C for 36 s, 728C for 36 s for 31 cycles (predetermined linear ampli®cation conditions) then a ®nal extension at 728C for 7 min. The products of PCR (10 ml) were electrophoresed on a 2% agarose gel and stained with ethidium bromide. UV uorescence was used to measure the intensity of product and 18S (control) bands using Gelblot software program (Ultra Violet Products In., Cambridge, UK). The PCR was performed in triplicate and each PCR product was resolved on two separate gels. Products were then normalized to 18S levels and the fold increase for the individual treatments was calculated.
Cell cycle analysis
The eect of 1a,25(OH) 2 D 3 in combination with the HDAC inhibitors on the cell cycle was measured by staining DNA with propidium iodide (PI). Brie¯y, T25 asks were seeded with 2.5610 5 sub-con¯uent, exponentially proliferating cells, exposed to 100 nM 1a,25(OH) 2 D 3 alone or combined with either 300 mM NaB or 15 nM TSA at times 0 (and re-dosed after 48 h in 72 and 96 h assays). After a total of 24, 48, 72 and 96 h, cultures were harvested by trypsinizing, counted and 1610 6 cells were stained with PI buer (10 mg/ml PI, 1%(w/v) tri-sodium citrate, 0.1%(v/v) Triton X-100, 100 mM sodium chloride (Sigma)). Cell cycle distribution was determined using a Becton-Dickinson Flow Cytometer and CellFIT Cell-Cycle Analysis software.
Measurement of apoptosis
To investigate further the mechanism of growth inhibition we examined the induction of apoptosis by the combination of 1a,25(OH) 2 D 3 in combination with the HDAC inhibitors (NaB and TSA) in a similar manner as the cell cycle analysis. Brie¯y, T25¯asks were seeded with 2.5610 5 sub-con¯uent, exponentially proliferating cells and exposed to 100 nM 1a,25(OH) 2 D 3 alone or combined with 15 nM TSA or 300 mM NaB at times 0 and re-dosed after 48 h. At 72 h parallel cultures were harvested. Apoptosis was assessed by measuring DNA fragmentation (TUNEL based assay) and mitochondrial membrane integrity (¯uorescent dye dimerization).
To measure the extent of DNA fragmentation total cells, both in the medium and those adhering to the plastic, were harvested and ®xed in 1% methanol-free formaldehyde for 15 min and washed in PBS. The cell concentration was adjusted to 1610 6 cells/ml and cells were further ®xed in 5 ml of 70% ethanol at 7208C. Single-and double-stranded DNA breaks were labelled with bromodeoxyuridine triphosphate (BrD-UTP) for 40 min at 378C using terminal transferase (Boehringer Mannheim, Indianapolis, IN, USA). Cells were permeabilized with 300 mM % Triton-X 100 in PBS containing 0.5% BSA and DNA breaks were tagged by BrDU and identi®ed using a FITC conjugated anti-BrDU antibody. Cells were stained with propidium iodide (PI) for 30 min and green¯uorescence was measured by FACS analysis at 510 ± 550 nm (Li and Daryzynkiewicz, 1995) .
The mitochondrial membrane integrity was also measured in a separate aliquot of harvested cells using the ApoAlert TM Mitochondrial Membrane Sensor Kit (Clonetech Laboratories, Inc., Basingstoke, UK), according to the manufacturer's instructions. Cells were peleted (1300 r.p.m. for 5 min), washed in 1 ml of PBS and then re-suspended in 1 ml of diluted Mitosensor reagent (1 ml/1 ml incubation buer). After incubating the cells at 378C in 5% CO 2 with Mitosensor reagent for 20 min, 1 ml of incubation buer was added and the cells were centrifuged for 5 min at 1300 r.p.m. Finally the cells were re-suspended in a further 500 ml of incubation buer.
Analysis of the cells was carried out with a¯uorescent microscope using a band-pass ®lter (detects¯uorescein and rhodamine), by placing 10 ml of cell suspension on a slide and air-drying in the dark before viewing. The mitosensor dye aggregates in the mitochondria of healthy cells and¯uoresces red against a backdrop of green monomeric cytoplasmic staining. However, in apoptotic cells, loss of mitochondrial membrane potential is an initial characteristic event and as a result, the dye cannot accumulate in the mitochondria and remains as monomers throughout the cells which¯uoresce green.
Statistical analysis
The interactions of two compounds were assessed by measuring the mean of either vitamin D 3 compound or HDAC inhibitor (NaB or TSA) acting alone or in combination (Campbell et al., 1998) . The mean observed combined eect was compared to the individual eects of the agents added together using the Student's t-test. Classi®cation of the eects were as follows: synergistic eects were those with an experimental value signi®cantly greater than the predicted value, additive eects were those where the experimental value did not signi®cantly dier from the predicted value, sub-additive eects were those where the experimental value was signi®cantly less than the predicated value.
